- Home
- RXRX
as 07-04-2025 11:37am EST
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | SALT LAKE CITY |
| Market Cap: | 2.0B | IPO Year: | 2021 |
| Target Price: | $7.00 | AVG Volume (30 days): | 32.1M |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.82 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.79 - $12.36 | Next Earning Date: | 08-07-2025 |
| Revenue: | $59,790,000 | Revenue Growth: | 29.32% |
| Revenue Growth (this year): | 23.51% | Revenue Growth (next year): | 53.87% |
Latest Recursion Pharmaceuticals Inc. News
RXRX Breaking Stock News: Dive into RXRX Ticker-Specific Updates for Smart Investing
Insider Monkey
10 days ago
Morgan Stanley Trims Recursion (RXRX) Price Target, Maintains Equal Weight Rating
Zacks
15 days ago
Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors
MT Newswires
19 days ago
Morgan Stanley Cuts Recursion Pharmaceuticals Price Target to $5 From $8, Maintains Equalweight Rating
Motley Fool
20 days ago
Is This Beaten-Down Cathie Wood Artificial Intelligence (AI) Stock a Buy?
BioPharma Dive
25 days ago
Insmed surges on lung drug data; Recursion cuts staff
Motley Fool
25 days ago
Why Recursion Pharmaceuticals Was Bouncing Higher on Tuesday
MT Newswires
25 days ago
Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday
MT Newswires
a month ago
Recursion Cuts 20% of Workforce, Extends Cash Runway to Late 2027
Compare RXRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RXRX Recursion Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.